JP2016513112A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513112A5
JP2016513112A5 JP2015558195A JP2015558195A JP2016513112A5 JP 2016513112 A5 JP2016513112 A5 JP 2016513112A5 JP 2015558195 A JP2015558195 A JP 2015558195A JP 2015558195 A JP2015558195 A JP 2015558195A JP 2016513112 A5 JP2016513112 A5 JP 2016513112A5
Authority
JP
Japan
Prior art keywords
alkyl
heterocyclyl
aryl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015558195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513112A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016881 external-priority patent/WO2014127350A1/en
Publication of JP2016513112A publication Critical patent/JP2016513112A/ja
Publication of JP2016513112A5 publication Critical patent/JP2016513112A5/ja
Pending legal-status Critical Current

Links

JP2015558195A 2013-02-18 2014-02-18 治療的潜在能力を有するバソプレッシン受容体のモジュレーター Pending JP2016513112A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361765968P 2013-02-18 2013-02-18
US201361765956P 2013-02-18 2013-02-18
US61/765,956 2013-02-18
US61/765,968 2013-02-18
PCT/US2014/016881 WO2014127350A1 (en) 2013-02-18 2014-02-18 Modulators of vasopressin receptors with therapeutic potential

Publications (2)

Publication Number Publication Date
JP2016513112A JP2016513112A (ja) 2016-05-12
JP2016513112A5 true JP2016513112A5 (cg-RX-API-DMAC10.html) 2017-03-23

Family

ID=51354614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558195A Pending JP2016513112A (ja) 2013-02-18 2014-02-18 治療的潜在能力を有するバソプレッシン受容体のモジュレーター

Country Status (6)

Country Link
US (2) US20150376198A1 (cg-RX-API-DMAC10.html)
EP (1) EP2956441A4 (cg-RX-API-DMAC10.html)
JP (1) JP2016513112A (cg-RX-API-DMAC10.html)
CN (1) CN105263910A (cg-RX-API-DMAC10.html)
CA (1) CA2901577A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014127350A1 (cg-RX-API-DMAC10.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011272738B2 (en) 2010-07-01 2015-08-20 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
LT2858989T (lt) 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
BR112014028585B1 (pt) 2012-05-17 2020-12-22 Genentech , Inc processo para fabricação de aminoácidos, e seus intermediários
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
JP6629855B2 (ja) * 2014-11-14 2020-01-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft スピロチアゾロン
WO2016086357A1 (en) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
CN105622528B (zh) * 2016-02-01 2017-12-15 新乡医学院第一附属医院 一种治疗肺动脉高压的化合物及其应用
CA3021678A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
WO2017192844A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
RU2018145734A (ru) 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
PT3595665T (pt) 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
WO2019003433A1 (ja) * 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
SG11202001498QA (en) * 2017-09-05 2020-03-30 Blackthorn Therapeutics Inc Vasopressin receptor antagonists and products and methods related thereto
KR102790657B1 (ko) * 2017-09-15 2025-04-02 아제반 파마슈티칼스, 인코퍼레이티드 뇌 손상을 치료하기 위한 조성물 및 방법
CN111417394B (zh) 2017-10-19 2023-11-07 帝人制药株式会社 苯并咪唑衍生物及其用途
WO2019112457A1 (en) 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
CA3045644C (en) 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
JP7337174B2 (ja) 2018-09-18 2023-09-01 ニカング セラピューティクス, インコーポレイテッド Srcホモロジー-2ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
JP7627343B2 (ja) * 2020-11-26 2025-02-05 シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド 新規ベンズアゼピンスピロ環式誘導体
WO2022174256A1 (en) * 2021-02-12 2022-08-18 The Scripps Research Institute Small molecule activators of yap transcriptional activity for regenerative organ repair
MX2024002173A (es) 2021-08-18 2024-03-26 Chemocentryx Inc Compuestos de arilsulfonilo como inhibidores de ccr6.
IL310368A (en) 2021-08-18 2024-03-01 Chemocentryx Inc Arylsulfonyl(hydroxy)piperidines as CCR6 inhibitors
CN118475583A (zh) * 2021-10-26 2024-08-09 瓦索卡地亚公司 Gpr39蛋白的拮抗剂
CN114394931B (zh) * 2022-01-30 2023-07-11 西安交通大学 具有血管舒张活性的单萜生物碱及其提取方法和应用
WO2023243601A1 (ja) 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物
WO2024050109A2 (en) * 2022-09-02 2024-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and compositions for controlling jet lag, chronotype, or circadian rhythm
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas
WO2025224085A1 (en) * 2024-04-23 2025-10-30 Universitat De Barcelona Compounds capable of acting on s1r as well as on seh and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3607993A1 (de) * 1986-03-11 1987-09-17 Basf Ag Verfahren zur herstellung von diaziridinen und produkte daraus
FR2624857B1 (fr) * 1987-12-16 1991-03-22 Irceba Derives de nicotinoyl-piperazine, procede de preparation et utilisation en therapeutique
JPH09505310A (ja) * 1993-11-16 1997-05-27 メルク エンド カンパニー インコーポレーテッド ピペリジンショウノウスルホニルオキシトシン拮抗剤
EP0850222B1 (en) * 1996-06-29 2003-05-28 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
GB2326639A (en) * 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
ES2125206B1 (es) * 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
JP2006505570A (ja) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
WO2006074025A1 (en) * 2004-12-30 2006-07-13 Janssen Pharmaceutica N.V. Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
TW200815426A (en) * 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
KR101050558B1 (ko) * 2006-12-08 2011-07-19 에프. 호프만-라 로슈 아게 V1a 수용체 길항제로서 작용하는 인돌
WO2009019219A2 (en) * 2007-08-03 2009-02-12 Solvay (Société Anonyme) Methods of using a solvent or a foam blowing agent
EP2477498A4 (en) * 2009-09-14 2013-02-27 Merck Sharp & Dohme INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
WO2012024179A1 (en) * 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Substituted amide derivatives as dgat-1 inhibitors
JP6130827B2 (ja) * 2011-05-17 2017-05-17 塩野義製薬株式会社 ヘテロ環化合物

Similar Documents

Publication Publication Date Title
JP7241856B2 (ja) ビス第四級アンモニウム化合物及びその製造方法と使用
RU2020121152A (ru) Твердые формы ингибитора калликреина плазмы и их соли
JP2021508686A5 (cg-RX-API-DMAC10.html)
JP2015506382A5 (cg-RX-API-DMAC10.html)
RU2016151727A (ru) Нейроактивные стероиды, композиции и их применения
RU2016137524A (ru) Амидные соединения для лечения опосредованных комплементом нарушений
JP2017531020A5 (cg-RX-API-DMAC10.html)
RU2018115569A (ru) Оксаспиропроизводное, способ его получения и его применения в лекарственных средствах
BR122017023795B1 (pt) Metodo para preparaqao de composiçao farmaceutica
JP2021527638A5 (cg-RX-API-DMAC10.html)
JP2011523412A5 (cg-RX-API-DMAC10.html)
RU2014122335A (ru) ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGluR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
RU2018139276A (ru) Полиморфные модификации n-[(3-фтор-4-метоксипиридин-2-ил)метил]-3-(метоксиметил)-1-({ 4-[(2-оксопиридин-1-ил)метил]фенил} метил)пиразол-4-карбоксамида и их соли
JP2015522018A5 (cg-RX-API-DMAC10.html)
JP2015531764A5 (cg-RX-API-DMAC10.html)
RU2016150326A (ru) Производные изоиндолина для применения в лечении вирусной инфекции
JP2023535815A5 (cg-RX-API-DMAC10.html)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2023549187A5 (cg-RX-API-DMAC10.html)
JP2019529460A5 (cg-RX-API-DMAC10.html)
KR101747486B1 (ko) 동통 치료제
JP2014529584A5 (cg-RX-API-DMAC10.html)
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами
JP2024116269A (ja) 神経因性疼痛の治療におけるフェニルキノリノン系誘導体およびフラボノイド系誘導体の使用
CN102653539B (zh) 一种抗血小板聚集化合物及其药物组合